PF-00562271 Besylate

For research use only. Not for use in humans.

目录号:S2672 别名: PF-562271 Besylate

PF-00562271 Besylate Chemical Structure

CAS No. 939791-38-5

PF-00562271 Besylate (PF-562271) 是PF-562271的苯磺酸盐,是一种有效的,ATP竞争性,可逆的FAK抑制剂,IC50为1.5 nM,作用于Pyk2比作用于FAK效果低10倍左右,比作用于其他蛋白激酶(除了一些CDKs)选择性高100倍以上。Phase 1。

规格 价格 库存 购买数量  
RMB 2204.74 现货
RMB 3851.06 现货
RMB 10401.3 现货
RMB 14144.13 现货
RMB 24324.3 现货
RMB 46437.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的PF-00562271 Besylate发表文献18篇:

客户使用该产品的4个实验数据:

  • Mol Ther 2012 20(5), 972-83. PF-00562271 Besylate purchased from Selleck.

  • Pharmacological inhibition of optoFAK with the ATP-competitive FAK inhibitor PF-00562271. OptoFAK expressing SC4 cells were serum-starved for 24 h in the absence or presence of PF-00562271 (1 mM) before being illuminated for 10 min with blue light (451 nm, 2 μmol m-2 s-1) or kept in the dark.

    Cell Signal, 2018, 42:176-183. PF-00562271 Besylate purchased from Selleck.

  • The migration index enhanced by CX3CL1 was dramatic reduced using Bosutinib and PF-00562271. CX3CL1-only group as control. Scale bar = 200 μm. The experiments were repeated three times. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001.

    J Cancer, 2018, 9(19):3603-3612. PF-00562271 Besylate purchased from Selleck.

  • SGC-7901 and MGC-803 cells were treated with OLFM4-sh lentivirus or FAK inhibitor (PF) alone, or co-treated with OLFM4-sh lentivirus and PF. Cellular invasive ability was measured by transwell assay after indicated treatment. Data are expressed as mean ± standard deviation from three independent experiments. One was analysis of variance (ANOVA) with Bonferroni T post-test was used to analysis the data. *P < 0.05, ***P < 0.001; ##P < 0.01, ###P < 0.001 VS. OLFM4-sh group.

    BMB Rep, 2015, 48(11):630-5. PF-00562271 Besylate purchased from Selleck.

产品安全说明书

FAK抑制剂选择性比较

生物活性

产品描述 PF-00562271 Besylate (PF-562271) 是PF-562271的苯磺酸盐,是一种有效的,ATP竞争性,可逆的FAK抑制剂,IC50为1.5 nM,作用于Pyk2比作用于FAK效果低10倍左右,比作用于其他蛋白激酶(除了一些CDKs)选择性高100倍以上。Phase 1。
靶点
FAK [1]
(Cell-free assay)
PYK2 [1]
(Cell-free assay)
CDK2/CyclinE [1]
(Cell-free assay)
CDK3/CyclinE [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
1.5 nM 13 nM 30 nM 47 nM 58 nM
体外研究

在重组酶实验中, PF-562271 Besylate选择性抑制FAK 和 Pyk2 酪氨酸激酶活性,IC50分别为1.5 nM 和14 nM。在细胞实验中,PF-562271 作用于FAK的IC50值为5 nM,比作用于其他激酶靶点选择性更高。[1] 在二维培养中,PF-562271 抑制FAK WT,FAK−/− 和FAK 激酶缺乏(KD)的细胞增殖,IC50分别为3.3 μM, 2.08 μM 和 2.01 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 cell NWHwellQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWrsbHNYUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{N{[2JO69VQ>? MVTTRW5ITVJ?
human SW982 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXLJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zNlgzKM7:TR?= NEGzfYJUSU6JRWK=
human KM12 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlvQTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zPFU2PyEQvF2= NVPqR445W0GQR1XS
human COLO-205 cell M1PjbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXztcXZnUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVIxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEi2OVgh|ryP MYnTRW5ITVJ?
human COLO-829 cell MnKzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYLJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vOEK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PjF5NjFOwG0> NFfMT5FUSU6JRWK=
human MG-63 cell NFHDeoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVOzdpJ1UW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDB4M{eg{txO M{WyOXNCVkeHUh?=
human IGROV-1 cell NXnxbIY3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUDlZ5RWUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56MUCzPEDPxE1? MYfTRW5ITVJ?
human NCI-H650 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUHxZlNLUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOEOxOVQh|ryP M4XoXnNCVkeHUh?=
human RT-112 cell M3jJUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1;JSGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDR4IN88US=> MnHMV2FPT0WU
human BCPAP cell NW\MeItrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnCbZlKdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xOTJ6ODFOwG0> M33vNHNCVkeHUh?=
ALL-PO cell MoHFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjvR4pYUW6qaXLpeIlwdiCxZjDoeY1idiCDTFytVG8h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjBzNUi0JO69VQ>? M3nDe3NCVkeHUh?=
human KYSE-270 cell NX7nO5MyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnyfnRKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNlcxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yNEexOEDPxE1? Ml23V2FPT0WU
human 8305C cell M2jQcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2Xt[GlvcGmkaYTpc44hd2ZiaIXtZY4hQDNyNVOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA6QTB2IN88US=> MXzTRW5ITVJ?
NCI-H810 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXrjcYJpUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMUC3O|Yh|ryP NXvvR|JqW0GQR1XS
human CAL-33 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGC4NJNKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTJ7M{ig{txO NIfaVoFUSU6JRWK=
human AN3-CA cell M1HrOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2e1SmlvcGmkaYTpc44hd2ZiaIXtZY4hSU5|LVPBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOTh4NzFOwG0> MlXvV2FPT0WU
human NKM-1 cell NITw[2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6yO|UxPiEQvF2= MmDmV2FPT0WU
human BPH-1 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjPS|JKdmirYnn0bY9vKG:oIHj1cYFvKEKSSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zQDd4NjFOwG0> MVPTRW5ITVJ?
human MES-SA cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoHsTY5pcWKrdHnvckBw\iCqdX3hckBOTVNvU1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMxPjh{IN88US=> MWXTRW5ITVJ?
human CAL-62 cell MoHBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|E6ODlizszN M2rHe3NCVkeHUh?=
human KYSE-150 cell NUXBNmtQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2izN2lvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT2xOVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN3MkO2JO69VQ>? MWfTRW5ITVJ?
human SK-UT-1 cell MmDMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MorVTY5pcWKrdHnvckBw\iCqdX3hckBUUy2XVD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PDZ2NzFOwG0> MX7TRW5ITVJ?
human HUTU-80 cell M2[0VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ1QDh4IN88US=> NWGzeZpuW0GQR1XS
human SIG-M5 cell MmD1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJHNKTy2PNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFg1QDdizszN MlT6V2FPT0WU
human AGS cell NWfpemVWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLjS5FKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVIyOjRizszN M1TNVXNCVkeHUh?=
human ST486 cell NVPKS454T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjF[WFKdmirYnn0bY9vKG:oIHj1cYFvKFOWNEi2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42OzJ5ODFOwG0> MW\TRW5ITVJ?
human HSC-2 cell NWHNZ2dZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWDYPXlvUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTN7NTFOwG0> M{DDe3NCVkeHUh?=
human BC-1 cell MlHTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYm2doNIUW6qaXLpeIlwdiCxZjDoeY1idiCEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OTZ4NDFOwG0> M1jaN3NCVkeHUh?=
human CGTH-W-1 cell NYL1SWpoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4fPeGlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZzNke5JO69VQ>? MVjTRW5ITVJ?
human MZ1-PC cell NXv4fHk{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFLIe5RKdmirYnn0bY9vKG:oIHj1cYFvKE2cMT3QR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjJ|MUKg{txO M3vrfnNCVkeHUh?=
human SW1710 cell M4\kW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\kbHhKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjJ4Mkig{txO NUj4SpQyW0GQR1XS
human EW-13 cell NFvzOnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkPuTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlM1PjZizszN MlTzV2FPT0WU
human U251 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXvCPXdDUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44PDB|MTFOwG0> M3q5OnNCVkeHUh?=
human NCI-H460 cell NXOzbG84T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFyweodKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFYxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yNEizPUDPxE1? MmrmV2FPT0WU
human DU-4475 cell NF7ucGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4C2eWlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTR5NUmg{txO NUDMZ2dXW0GQR1XS
human MFE-296 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmKyTY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkm2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41Pzd7MjFOwG0> MmrnV2FPT0WU
human DU-145 cell NGLncGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjkZYVtUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR7MUG4JO69VQ>? MV;TRW5ITVJ?
human MDA-MB-231 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{XqdGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNEm1O|Ih|ryP M17MOXNCVkeHUh?=
human SNU-387 cell Mk\zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfvNI1KdmirYnn0bY9vKG:oIHj1cYFvKFOQVT2zPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV{OEKg{txO NWToc|QxW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 PF-562271 Besylate作用于一些人类皮下移植瘤模型,抑制肿瘤生长,这种作用存在剂量依赖性,且产生最大肿瘤抑制效果,按25 到 50 mg/kg剂量作用于PC-3M, BT474, BxPc3, 和LoVo细胞,每天两次,抑制达78%到94%,没有发生体重降低,生病或死亡。[1]PF-562271 按25 mg/kg剂量口服处理皮下和骨转移PC3M-LUC-5233移植瘤模型,显著降低肿瘤进展。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

重组激酶实验和酶动力学:

纯化激活的FAK激酶域 (第 410–689位氨基酸)与 50 μM ATP ,和每孔 10 μg Glu 和 Tyr, p(Glu/Tyr)随机肽聚合物,在激酶buffer [50 mM HEPES (pH 7.5), 125 mM NaCl, 和 48 mM MgCl2] 中反应15分钟。使用从1 μM连续稀释的PF-562271 进行p(Glu/Tyr)磷酸化。实验中每种实验浓度重复三次。使用通用 抗磷酸酪氨酸 (PY20) 抗体和随后的辣根过氧化物酶(HRP)标记的羊抗鼠IgG抗体检测p(Glu/Tyr) 的磷酸化。加入HRP 底物,加入终止液(2 M H2SO4),在450 nm处测定吸光值。使用Hill-Slope 模型测定IC50值。使用KinaseProfiler 选择性筛选服务系统通过UpState生物技术进行广谱激酶选择谱研究。
细胞实验:

[2]

- 合并
  • Cell lines: 鳞状细胞癌(SCC)
  • Concentrations: 0 到1 μM
  • Incubation Time: 72小时
  • Method:

    细胞接种48小时后,加入PF-562271。加入冰冻25% 三氯乙酸 (TCA) 溶液,混合细胞,3天后,使用 Sulforhodamine B(SRB) 染料染色。使用1% 冰醋酸冲洗实验板,烘干,然后再悬浮在10 mM Tris buffer, pH 10.5中,然后在 540 nm处测定吸光值。拟合曲线,使用GraphPad Prism 4 软件从6次重复测定中获得IC50值。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: PC-3M, BT474, BxPc3, LoVo, U87MG, H125 和H460细胞皮下注射到无胸腺雌性小鼠右侧
  • Dosages: ≤100 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (21.03 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 665.66
化学式

C21H20F3N7O3S.C6H6O3S

CAS号 939791-38-5
储存条件 粉状
溶于溶剂
别名 PF-562271 Besylate

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00666926 Completed Drug: PF00562271 Head and Neck Neoplasm|Prostatic Neoplasm|Pancreatic Neoplasm Verastem Inc. December 2005 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    We are planning both in vitro and in vivo experiments and want to know how to reconstitute the drug for these purposes?

  • 回答:

    PF-00562271 has poor solubility in DMSO and water. Its solubility in DMSO is only 0.4mg/ml. In a previous literature report (http://www.ncbi.nlm.nih.gov/pubmed/18339875), the author used 5% Gelucire to formulate the compound. You can also consider other co-solvents such as PEG400, CMC, Tween80, and Captisol.

  • 问题 2:

    Can you provide with a few common vehicles for PF-00562271, S2672 for use as oral gavage?

  • 回答:

    S2672 PF-00562271 can be dissolved in 0.5% CMC Na at 30 mg/ml as a suspension. If 4% DMSO can be used in your experiment, it will help dissolving the suspension more homogeneously.

免费分装抑制剂

FAK Signaling Pathway Map

相关FAK产品

Tags: 购买PF-00562271 Besylate | PF-00562271 Besylate供应商 | 采购PF-00562271 Besylate | PF-00562271 Besylate价格 | PF-00562271 Besylate生产 | 订购PF-00562271 Besylate | PF-00562271 Besylate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID